Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel

Stock Information for Pluristem Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pluristem Therapeutics Inc.

Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock
Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Kuehn Law Encourages Investors of Capricor Therapeutics, Inc. to Contact Law Firm
Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.